An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
List view / Grid view
Scientists have developed a 3D lung-on-a-chip model of the distal lung and alveolar structures, enabling the study of COVID-19.
Researchers have developed a novel organ-on-a-chip model of sickle cell disease to improve personalised medicine.
Researchers have reviewed lung-on-a-chip technologies, finding they are useful for representing the various disease pathologies.
A liver-on-a-chip model has been developed to more fully represent the natural progression of NAFLD than previous models.
A team has used their new organs-on-a-chip system to replicate the interactions between the brain, liver and colon.
The newly developed chip includes heart and breast cancer tissues and could be used to predict the cardiac toxicity of chemotherapeutic drugs.
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
Researchers have developed a device which mimics how blinking and tear movement effect the cornea for use in testing ophthalmic drugs and ocular research.
Researchers have demonstrated that stem cells attract neurons with different strengths and that connections between the two may be vital for cancer stem cell function.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
The model was tested on a panel of drugs that are both still on the market or have been recalled due to adverse effects and was able to show their toxicity.
Researchers have engineered a chip which allows 3D modelling of the blood-brain-barrier and has provided insight into how astrocytes facilitate transport of molecules.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Researchers have made a ‘Liver-Chip’ which is able to demonstrate the toxic effects of drug candidates and compounds in human patients.